




MSD • Wellcome Trust
Hilleman Laboratories
Developing vaccines for global health

**Hilleman
Laboratories**



If I had to name a person who has done more for the benefit of human health, with less recognition than anyone else, it would be Maurice Hilleman. Maurice should be recognized as the most successful vaccinologist in history.”

-ROBERT GALLO, Co - discoverer of HIV virus

OUR MISSION

Creating new vaccines in areas of unmet need as well as adapting existing vaccines for more effective delivery in low-income nations



ORGANIZATIONAL STRUCTURE

Board Of
Directors

Hilleman
Management

Strategic
Advisory
Group

Merck & Wellcome Trust Joint-Venture



wellcometrust

WELLCOME TRUST, UK
Famous for its contribution to
Biomedical Research

Dr. Gerd Zettlmeissl
Chairman

Prof. Gagandeep Kang
Director (Wellcome Trust)

Prof. Gordon Dougan
Director (Wellcome Trust)



MSD
BeWell

MSD (Merck) -
A renowned global
vaccine development
corporation.

Dr. Julie Gerberding
Director (Merck)

Mr. Sanat Chattopadhyay
Director (Merck)

Mr. Michael T Nally
Director (Merck)



MSD - Wellcome Trust
Hilleman Laboratories
Developing vaccines for global health

MSD – Wellcome Trust,
Hilleman Laboratories
Independent Organization



Current Projects



Heat Stable Rotavirus Vaccine

☒ Hilleman Laboratories has begun to work on the development of a thermostable oral rotavirus vaccine to allow for greater temperature consistency and less reliance on exact storage timing and refrigeration.

Optimized Cholera Vaccine

☒ Hilleman Laboratories in collaboration with Gotovax AB (a University of Gothenburg spin-off biopharmaceutical company) aims to deliver a high impact Oral Cholera vaccine at a significantly more affordable price than the ones currently available in the market.

ETEC Vaccine

☒ Our ETEC vaccine project involves generation of genetically modified vaccine strains that contain highly expressed immunogenic antigens selected using in-silico reverse vaccinology approaches together with publically available whole genome sequence data.

Current Projects (CONT.)



Shigella Vaccine

Our Shigella vaccine is a collaboration with National Institute of Cholera and Enteric Diseases, Kolkata (NICED) and the Indian Council of Medical Research (ICMR). Hilleman Labs and NICED will develop vaccines against the infection and establish proof-of-concept in the clinic. Our partner, ICMR, brings a wealth of expertise in clinical research and development of vaccines. Together, we will accelerate development of our novel Shigella vaccine.

Low-cost Meningococcal Conjugate Vaccine

Hilleman Labs uses a two-pronged strategy to develop low-cost vaccine for prevention of invasive meningococcal disease - conventional methods to develop conjugate vaccines covering A,C,Y,W & X serogroups, and a novel method using synthetic organic chemistry to create short oligosaccharides. Our method has the potential to significantly reduce costs and create new IP, allowing developing country manufacturers undertake more conjugate vaccine development projects.

OUR MODEL FOR SUCCESS

Innovative Ideas

Innovative Ideas
Ideas are pre-selected based upon global impact, feasibility of the problem, competitive landscape for development purposes.

R & D

R & D
Innovations are converted into powerful vaccines through the process of translational Research and Development.

MFG & Sales

Manufacturing & Sales
Our vision as a non-profit company allows us to build partnerships with vaccine manufacturers who assemble our products and sell them.

Income

Sustainability
Funding for our business model is primarily obtained through Innovative Financing and Product Sales. To date our focus has been on vaccines and infectious diseases.

Hilleman Lab's Unique Approach



What makes Hilleman Laboratories different?

- ☒ Hilleman Laboratories has designed vaccines which directly meets the needs of the developing world.
- ☒ These vaccines can be orally administered, are affordable for poor communities, and are also heat-stable up to 45° C.

Progression



2012

MSD & Wellcome Trust open R&D facility in Jamia Hamdard University, New Delhi, INDIA




Early 2014

Announced collaboration with Gotovax AB-Sweden in order to develop a high impact Cholera vaccine.




Late 2014

Hilleman Labs signs MoU with Bangladesh based icddr-b in order to fast track clinical trials




2015

Preclinical success of Meningococcal & HiB vaccines indicates predictive results. New vaccines are cost effective & meet needs of developing countries.



2016

Rotavirus and Cholera vaccines proceed into Stage II of clinical trials. Novel ETEC vaccine initiated



Present

Hilleman Labs announces collaboration with Kolkata based NICED to develop and commercialize a vaccine against Shigella.

Sustainability



☒ Hilleman Laboratories develops its vaccines through grants and project based funding.

☒ Vaccine Research & Development, is making substantial progress through partnerships, and sustainable development.

Vision



To be recognized as the Center of Excellence for early-stage development of vaccines by bringing together the scientific prowess of global partners and funders to benefit the world's poorest.



Forge Relationships strengthening public private partnerships in order to manufacture and commercialize vaccines at affordable cost.



Continue development of vaccines for various diseases affecting developing countries. Initiate registration stage for Rotavirus & Cholera vaccines.

Our Partners



CONNECT



THANK YOU